.Pharmacolibrary.Drugs.ATC.N.N04BC05

Information

Pramipexole is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome (RLS). It is approved and used clinically today.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult subjects after oral administration.

References

1. Soto, E, et al., & Trocóniz, IF (2010). Population in vitro-in vivo correlation model for pramipexole slow-release oral formulations. Pharmaceutical research 27(2) 340–349. DOI:10.1007/s11095-009-0027-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20039105

2. You, X, et al., & Lin, C (2020). Development of a Physiologically Based Pharmacokinetic Model for Prediction of Pramipexole Pharmacokinetics in Parkinson's Disease Patients With Renal Impairment. Journal of clinical pharmacology 60(8) 999–1010. DOI:10.1002/jcph.1593 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32090332

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)